These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21433070)

  • 1. Healthy users, healthy adherers, and healthy behaviors?
    Silverman SL; Gold DT
    J Bone Miner Res; 2011 Apr; 26(4):681-2. PubMed ID: 21433070
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
    Curtis JR; Delzell E; Chen L; Black D; Ensrud K; Judd S; Safford MM; Schwartz AV; Bauer DC
    J Bone Miner Res; 2011 Apr; 26(4):683-8. PubMed ID: 20939064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation.
    Delmas PD; Rizzoli R; Cooper C; Reginster JY
    Osteoporos Int; 2005 Jan; 16(1):1-5. PubMed ID: 15565349
    [No Abstract]   [Full Text] [Related]  

  • 4. Postmenopausal osteoporosis: another approach to management.
    Cole R
    J Fam Pract; 2010 Jun; 59(6):E1-7. PubMed ID: 20544058
    [No Abstract]   [Full Text] [Related]  

  • 5. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 6. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do not use bisphosphonate therapy indefinitely for fracture prevention.
    Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
    Papapoulos SE
    Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
    [No Abstract]   [Full Text] [Related]  

  • 10. [Update on treatment of postmenopausal osteoporosis].
    Body JJ
    Rev Med Brux; 2008 Sep; 29(4):301-9. PubMed ID: 18949981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of postmenopausal osteoporosis.
    Sambrook PN
    N Engl J Med; 1995 Nov; 333(22):1495-6. PubMed ID: 7477151
    [No Abstract]   [Full Text] [Related]  

  • 13. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture.
    Andrade SE; Majumdar SR; Chan KA; Buist DS; Go AS; Goodman M; Smith DH; Platt R; Gurwitz JH
    Arch Intern Med; 2003 Sep; 163(17):2052-7. PubMed ID: 14504118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials.
    Nguyen ND; Eisman JA; Nguyen TV
    J Bone Miner Res; 2006 Feb; 21(2):340-9. PubMed ID: 16526127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fewer fractures after just 6 months. Fast help for tired bones].
    MMW Fortschr Med; 2002 Nov; 144(48):61. PubMed ID: 12532551
    [No Abstract]   [Full Text] [Related]  

  • 18. Alendronate in postmenopausal osteoporosis.
    Liedholm H; Linné AB
    N Engl J Med; 1996 Mar; 334(11):733-4; author reply 734-5. PubMed ID: 8594442
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimising bisphosphonate treatment outcomes in postmenopausal osteoporosis: review and Italian experience.
    Rossini M; Di Munno O; Gatti D; Giannini S; Minisola S; Varenna M; Adami S
    Clin Exp Rheumatol; 2011; 29(4):728-35. PubMed ID: 21813068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.